A Win for Trabectedin in Excessive-Grade Myxoid Liposarcoma?

Photo of author

By Calvin S. Nelson

Neoadjuvant trabectedin (Yondelis) for high-grade myxoid liposarcoma (HG-MLPS) demonstrated noninferiority to the long-time normal of anthracycline-ifosfamide (AI), in accordance with new information from a beforehand accomplished trial.

Commonplace remedy was related to twice as many recurrences as in contrast with trabectedin, translating right into a 40% discount within the hazard for disease-free survival (DFS) in favor of trabectedin. The prespecified margin for noninferiority for relapse was HR >1.25, and two separate analyses confirmed that the chance of a real HR >1.25 was <5%, satisfying the prespecified vary for noninferiority.

The findings counsel that trabectedin is likely to be a substitute for normal neoadjuvant chemotherapy for HG-MLPS of the extremities or trunk, reported Alessandro Gronchi, MD, of the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, and co-authors within the Journal of Medical Oncology (JCO).

“The noninferiority of trabectedin versus AI could be useful since trabectedin has a much better acute tolerability profile, with decrease hematologic toxicity, no hair loss … and no long-term cardiac toxicity,” the authors said. “Sufferers with HG-MLPS are often 10 years youthful than sufferers with different widespread adult-type STS [soft-tissue sarcoma], making the avoidance of anthracyclines much more related for them in the long term.”

Considering the research’s limitations, “one may argue that the info from the ultimate evaluation of this expanded cohort assist the selection of trabectedin, presumably together with radiation remedy, when neoadjuvant remedy is a consideration for HG-MLPS,” they added. “Moreover, we consider it’s important to additional discover the prognostic correlation of present pathologic grading of HG-MLPS to enhance prognostic danger stratification for these sufferers.”

The findings got here from a randomized trial that did not exhibit the prevalence of histology-tailored remedy (HTT) versus AI. The trial, carried out by sarcoma analysis networks in Italy, Spain, France, and Poland, in contrast the 2 neoadjuvant methods within the 5 most typical forms of STS. AI prevailed throughout 4 of the 5 tumor sorts.

Investigators noticed a pattern towards improved DFS with trabectedin in sufferers with HG-MLPS, and trial enrollment was reopened to accrue extra sufferers with that one sort of STS.

As initially designed, the trial examined the speculation that HTT would result in superior outcomes versus normal AI, JCO Affiliate Editor Robert Maki, MD, famous in an accompanying editorial. As a substitute, the major evaluation confirmed that the reverse was true, as AI led to raised DFS (the first endpoint) and survival as in contrast with HTT.

When the trial was reopened to enrollment of extra sufferers with HG-MLPS, investigators additionally modified the first endpoint as to whether the chance that HTT was noninferior to AI for an odds ratio of >1.25 was lower than 5%. The brand new evaluation confirmed that HTT did meet the statistical necessities of noninferiority.

“The implications of such a discovering are essential, particularly that sufferers with one of many extra widespread sarcoma subtypes can profit from the much less poisonous trabectedin than AIM [anthracycline-ifosfamide-mesna],” stated Maki, of Memorial Sloan Kettering Most cancers Middle in New York Metropolis. “The issues concerning the trial design are equally clear. It was not potential to find out sort 1 or sort 2 error from a research by which sufferers had been enrolled with two completely different endpoints and two completely different research designs.”

“Are this research pattern measurement and small variety of occasions sufficient to offer convincing proof of the noninferiority of trabectedin in contrast with AIM for high-grade myxoid-round cell liposarcoma?” he added. “Whereas the survival curves and the results of a potential, randomized trial point out noninferiority of the much less poisonous remedy, the research design points complicate the interpretation.”

Clinicians can be left to their very own units to interpret and apply the info from the trial or discard them, “as it’s unlikely {that a} sizable research of neoadjuvant remedy can be examined once more on this prognosis within the foreseeable future, until new medicine which might be very lively in metastatic illness are discovered.”

Randomized trials are nonetheless possible for uncommon cancers with poor outcomes, however trial design should be custom-made to account for challenges of accrual and expectations for outcomes, Maki concluded.

Gronchi and colleagues reported outcomes for 101 sufferers with localized HG-MLPS originating in an extremity or the trunk wall. They had been randomized to trabectedin or normal AI. The first endpoint was 5-year DFS, and 5-year total survival (OS) was a secondary endpoint.

Throughout a median follow-up of 66 months, the trial had 22 recurrences, 15 within the AI arm and 7 within the trabectedin arm. Absolutely the numbers translated right into a DFS chance 0.86 for trabectedin and 0.73 for traditional remedy, and the OS possibilities had been 0.88 and 0.90, respectively.

The posterior chance of an HR >1.25 for DFS was 4.93%, assembly the Bayesian monitoring cutoff of <5%. A per-protocol evaluation involving 97 randomized sufferers yielded a posterior chance of HR >1.25 of three.63%, additionally supporting trabectedin noninferiority.

For OS, the general evaluation yielded an estimated HR of 1.20 for trabectedin versus AI, lowering to 1.03 within the per-protocol evaluation.

  • Charles Bankhead is senior editor for oncology and likewise covers urology, dermatology, and ophthalmology. He joined MedPage As we speak in 2007.


The research was supported by the European Union, the LYriCAN program of the French NCI, NetSarc, and DEPGYN.

Gronchi disclosed relationships with Novartis, Pfizer, Lilly, PharmaMar, Deciphera, Bayer, Nanobiotix, SpringWorks Therapeutics, and Boehringer Ingelheim.

Maki is an affiliate editor of the Journal of Medical Oncology however was recused from peer assessment of the manuscript. He disclosed relationships with PEEL Therapeutics, Bayer, Deciphera, Ipsen, Regeneron, Daiichi, Bayer, SpringWorks Therapeutics, Amgen, Astex Prescription drugs, Boehringer Ingelheim, Rain Therapeutics, BioAtla, C4 Therapeutics, Exelixis, Inhibrx, Presage Biosciences, SARC, SynOx, and TRACON Pharma, in addition to patent/royalty/mental property pursuits.

Major Supply

Journal of Medical Oncology

Supply Reference: Gronchi A, et al “Neoadjuvant chemotherapy in high-grade myxoid liposarcoma: Outcomes of the expanded cohort of a randomized trial from Italian, Spanish, French, and Polish sarcoma teams” J Clin Oncol 2024; DOI: 10.1200/JCO.23.00908.

Secondary Supply

Journal of Medical Oncology

Supply Reference: Maki R “Trials and tribulations in uncommon most cancers medical analysis” J Clin Oncol 2024; DOI: 10.1200/JCO.23.02137.

Please allow JavaScript to view the feedback powered by Disqus.

Leave a Comment